SM-Youtube

Year	Number of Results
1968	1
1973	1
1976	2
1979	1
1981	1
1982	1
1986	1
1990	1
1992	14
1993	21
1994	101
1995	311
1996	357
1997	402
1998	376
1999	397
2000	364
2001	398
2002	353
2003	331
2004	294
2005	340
2006	372
2007	339
2008	271
2009	291
2010	301
2011	294
2012	296
2013	312
2014	290
2015	240
2016	216
2017	217
2018	211
2019	205
2020	185
2021	136
2022	51
2023	36
2024	37

Year

Number of Results

1968

1973

1976

1979

1981

1982

1986

1990

1992

1993

1994

101

1995

311

1996

357

1997

402

1998

376

1999

397

2000

364

2001

398

2002

353

2003

331

2004

294

2005

340

2006

372

2007

339

2008

271

2009

291

2010

301

2011

294

2012

296

2013

312

2014

290

2015

240

2016

216

2017

217

2018

211

2019

205

2020

185

2021

136

2022

2023

2024

Page 1

Dopamine receptor pharmacology.

Seeman P, Van Tol HH. Seeman P, et al. Trends Pharmacol Sci. 1994 Jul;15(7):264-70. doi: 10.1016/0165-6147(94)90323-9. Trends Pharmacol Sci. 1994. PMID: 7940991 Review.

Investigational dopamine antagonists for the treatment of schizophrenia.

Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU. Wang SM, et al. Expert Opin Investig Drugs. 2017 Jun;26(6):687-698. doi: 10.1080/13543784.2017.1323870. Epub 2017 May 12. Expert Opin Investig Drugs. 2017. PMID: 28443355 Review.

Distinct Dopamine D₂ Receptor Antagonists Differentially Impact D₂ Receptor Oligomerization.

Wouters E, Marín AR, Dalton JAR, Giraldo J, Stove C. Wouters E, et al. Int J Mol Sci. 2019 Apr 4;20(7):1686. doi: 10.3390/ijms20071686. Int J Mol Sci. 2019. PMID: 30987329 Free PMC article.

Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.

Newman AH, Grundt P, Nader MA. Newman AH, et al. J Med Chem. 2005 Jun 2;48(11):3663-79. doi: 10.1021/jm040190e. J Med Chem. 2005. PMID: 15916415 Review. No abstract available.

Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting.

Orhan A, Nguyen C, Chan A, Herrstedt J. Orhan A, et al. Expert Opin Drug Metab Toxicol. 2024 Jun;20(6):473-489. doi: 10.1080/17425255.2024.2367593. Epub 2024 Jun 25. Expert Opin Drug Metab Toxicol. 2024. PMID: 38878283 Review.

Kinetics and pharmacology of the D1- and D2-like dopamine receptors in Japanese quail brain.

Kubíková L, Výboh P, Kostál L. Kubíková L, et al. Cell Mol Neurobiol. 2009 Sep;29(6-7):961-70. doi: 10.1007/s10571-009-9382-6. Epub 2009 Mar 28. Cell Mol Neurobiol. 2009. PMID: 19330447

Efficacy and Safety of Drugs for Gastroparesis: Dopamine Receptor Antagonists Should Not Be Considered as a Single Pharmacologic Entity.

Sanger GJ, Andrews PLR. Sanger GJ, et al. Gastroenterology. 2023 Aug;165(2):520-521. doi: 10.1053/j.gastro.2023.01.043. Epub 2023 Feb 16. Gastroenterology. 2023. PMID: 36801210 No abstract available.

Amisulpride.

[No authors listed] [No authors listed] Am J Health Syst Pharm. 2020 Nov 16;77(23):1917-1918. doi: 10.1093/ajhp/zxaa292. Am J Health Syst Pharm. 2020. PMID: 33196816 No abstract available.

Effects of dopamine antagonists in human eye accommodation.

Yeung L, Hung PT, Lin LL, Yang CH, Chiou GC. Yeung L, et al. J Ocul Pharmacol Ther. 2001 Feb;17(1):11-7. doi: 10.1089/108076801750125595. J Ocul Pharmacol Ther. 2001. PMID: 11322633 Clinical Trial.

Comment on: Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys.

Chong S, Comer SD. Chong S, et al. Neuropsychopharmacology. 2023 Nov;48(12):1703-1704. doi: 10.1038/s41386-023-01726-w. Epub 2023 Sep 8. Neuropsychopharmacology. 2023. PMID: 37684521 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

7,576 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Search Results

7,576 results

Results by year